BETHLEHEM, Pa., Aug. 19 /PRNewswire/ -- Particle Sciences Inc. has expanded its Combination Product (drug-eluting polymers) development and pilot production capabilities with the installation of a compounding, extrusion and injection molding line. The core of the pilot line, comprising a Haake twin-screw compounding extruder and Nissei 20T injection molder, enables the production of high-quality drug loaded polymeric devices. This addition gives Particle Sciences the ability to go from bench scale to clinical trial material production. Particle Sciences has recently completed Phase I of the development of a drug-eluting polymeric vaginal ring that demonstrated 30-day continuous release of a small molecule API. Particle Sciences has also developed and successfully demonstrated a proprietary approach to achieving zero-order release from polymeric drug delivery devices. "The installation of this line, and our continuing investment in related intellectual property, increases our capabilities, and positions Particle Sciences as an innovative developer of drug-eluting medical devices," commented Dr. Andrew Loxley, Director of New Technologies. "And coupled with our recently expanded clean room facilities, will allow us to provide our clients with Combination Product development services from conception through to clinical trials." For more information visit http://www.particlesciences.com
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
Contact: Maureen Cochran 610-861-4701
|SOURCE Particle Sciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved